1. Use of nDx 1 Software is only available to partners who are registered separately in Novomics.
2. You must pass the certification procedure on the next screen before you can use the software.
3. Click the "Certification" button to install it automatically on your connection PC.
* Contact us : +82-2-2068-3700
nProfiler® 1 Stomach Cancer Assay is a
molecular diagnostic test for patients who are diagnosed with stage Ⅱ and Ⅲ
gastric cancer after D2 gastrectomy and enables to stratify patients into
different risk parameters (Low, Intermediate, and High risk group). nProfiler®
1 Stomach Cancer Assay has been approved by MFDS as in vitro diagnostic medical
device (Product License No.17-865).
For more details, http://www.novomics.com/en/profiler/product.asp
Gastric cancer patients who are diagnosed with stage II and III after D2 gastrectomy are eligible for nProfiler® 1 Stomach Cancer Assay.
Service flow of nProfiler® 1 Stomach Cancer
Assay
The results of nProfiler® 1 Stomach Cancer
Assay are available within 14 days from the time of ordering the test.
This given period includes the full process
from sample collection to report delivery.
For more details,
http://www.novomics.com/en/profiler/service.asp
nProfiler® 1
Stomach Cancer Assay consists of Kit A and Kit B including 14 and 1 IVD
reagents, respectively.
These IVD reagents consist of RT-qPCR reagents (e.g. RT Mix, RT Buffer, etc), negative and positive control, and specific reagents for measurement of 9 gene expression levels.
nProfiler® 1 Stomach Cancer Assay measures
and analyses the expression level of gastric cancer related genes in real-time.
nProfiler® 1 Stomach Cancer Assay measures the expression level of specific genes in the extracted RNA from gastric cancer tissue after D2 gastrectomy using RT-qPCR. Then, the prognosis is predicted based on the expression level using algorithm.
nProfiler® 1 Stomach Cancer Assay measures the expression of 9 genes: 4 target genes (WARS, GZMB, CDX1, and SFRP4) and 5 reference genes (ACTB, ATP5E, HPRT1, GPX1, and UBB).
A threshold value of each gene is a
reference point that distinguishes high and low expression of a corresponding
gene. The prognosis and predictive classification are performed using a binary
signal based two tier system based on the expression level of 4 target genes.
First Tier: Classifying a group as a Low
risk group and no-benefit group when ΔCq values of GZMB and WARS are higher
than threshold values.
Second Tier-Prognosis: At least one ΔCq
value of GZMB and WARS is lower than the threshold value, classifying a group
as an Intermediate risk group when the ΔCq value of SFRP4 is lower than
threshold value and a group as a High risk group when the ΔCq value of SFPR4 is
higher than the threshold value.
Second Tier-Prediction: At least one ΔCq
value of GZMB and WARS is lower than the threshold value, classifying a group
as a no-benefit group when the ΔCq value of CDX1 is lower than threshold value
and a group as a chemotherapy-benefit group when the ΔCq value of CDX1 is
higher than the threshold value.
For more details,
http://www.novomics.com/en/profiler/algorithm.asp
nProfiler® 1 Stomach Cancer Assay
classifies patients into Low risk group (IM type: high expression of immune
genes), Intermediate risk group (EP type: high expression of epithelial gene
and low expression of immune genes), and High risk group (ST type: high
expression of stem-like gene and low expression of immune genes).
Additionally, the chemotherapy benefit
group are to be expected to benefit from adjuvant chemotherapy after
gastrectomy as they show relatively high proliferation rate. However, in case
of no-benefit group showing a low or high immune activity and low epithelial
characteristics, it is hard to expect for benefits of chemotherapy.
The report of nProfiler® 1 Stomach Cancer
Assay provides information on 5-year overall survival for the patients with
gastric cancer stage II and III after gastrectomy according to prognostic
group.
Patients are stratified into 3 prognostic
groups based on the level of gene expression and these are the 5-year overall
survival and 95% confidence interval (CI) for each group.
1) Low risk group: 82% (95%CI: 74.1-90.7)
2) Intermediate risk group: 66.2% (95%CI:60.6-72.3)
3) High risk Group: 55.7% (95% CI:
50.5-61.5)
For more details, http://novomics.com/en/profiler/interpreting.asp
The TNM staging classification is used to guide the treatment method for gastric cancer in current clinical practice. However, the differences in biological characteristics in gastric cancer patients in the same stage would bring different results on the effect of chemotherapy.
Physicians can use the result of nProfiler®
1 Stomach Cancer Assay as supplementary information to identify treatment
options in gastric cancer.